Fitzpatrick_2014_Atherosclerosis_235_384

Reference

Title : Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study - Fitzpatrick_2014_Atherosclerosis_235_384
Author(s) : Fitzpatrick AL , Irizarry MC , Cushman M , Jenny NS , Chi GC , Koro C
Ref : Atherosclerosis , 235 :384 , 2014
Abstract : OBJECTIVE: To evaluate associations between Lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with risk of dementia and its subtypes.
METHODS: Analysis were completed on 3320 participants of the Cardiovascular Health Study (CHS), a population-based longitudinal study of community-dwelling adults age >/=65 years followed for an average of 5.4 years. Baseline serum Lp-PLA2 mass was measured using a sandwich enzyme immunoassay and Lp-PLA2 activity utilized a tritiated-platelet activating factor activity assay. Cox proportional hazards regression assessed the relative risk of incident dementia with higher baseline Lp-PLA2 adjusting for demographics, cardiovascular disease (CVD) and risk factors, inflammation markers and apolipoprotein E (APOE) genotype.
RESULTS: Each standard deviation higher Lp-PLA2 mass and activity were related to increased risk of dementia (fully adjusted HR: 1.11 per SD, 95% CI: 1.00-1.24 for mass; HR: 1.12 per SD, 95% CI: 1.00-1.26 for activity). Persons in the highest quartile of Lp-PLA2 mass were 50% more likely to develop dementia than those in the lowest quartile in adjusted models (HR: 1.49; 95% CI: 1.08-2.06). Among dementia subtypes, the risk of AD was increased two-fold in the highest compared to lowest quartile of Lp-PLA2 mass (adjusted HR: 1.98, 95% CI: 1.22-3.21). Results were attenuated in models of mixed dementia and VaD. Lp-PLA2 activity also doubled the risk of mixed dementia in the highest compared to lowest quartile (HR: 2.21, 95% CI: 1.12-4.373). INTERPRETATION: These data support Lp-PLA2 as a risk factor for dementia independent of CVD and its risk factors. Further study is required to clarify the role of Lp-PLA2-related mechanisms in dementia subtypes.
ESTHER : Fitzpatrick_2014_Atherosclerosis_235_384
PubMedSearch : Fitzpatrick_2014_Atherosclerosis_235_384
PubMedID: 24929287

Related information

Inhibitor Rilapladib

Citations formats

Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C (2014)
Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study
Atherosclerosis 235 :384

Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C (2014)
Atherosclerosis 235 :384

Array
(
    [id] => 44440
    [paper] => Fitzpatrick_2014_Atherosclerosis_235_384
    [author] => Fitzpatrick AL || Irizarry MC || Cushman M || Jenny NS || Chi GC || Koro C
    [year] => 2014
    [title] => Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study
    [journal] => Atherosclerosis
    [volume] => 235
    [page] => 384
    [medline] => 24929287
    [abstract] => Fitzpatrick_2014_Atherosclerosis_235_384
    [kin_reference] => 
    [mutation] => 
    [kinetic_parameter] => 
    [inhibitor] => Rilapladib
    [kin_value] => 
    [substrate] => 
    [gene_locus] => Array
        (
        )

    [family] => 
    [interact_gene_locus] => 
    [xenobiotic_sensitivity] => 
    [news] => 
    [likid_reference] => 
    [lip_reference] => 
    [gene_locus_frgt] => 
    [structure] => 
    [comment] => 
    [chemical] => 
    [arpigny_jaeger] => 
    [reactivator] => 
    [disease] => 
    [enzyme] => 
    [risk_factor] => 
    [tissue] => 
    [sub_tissue] => 
    [activity] => 
    [specific_activity] => 
    [disease_by_interaction] => 
    [abstract_text] => Array
        (
            [id] => 112687
            [longtext] => Fitzpatrick_2014_Atherosclerosis_235_384
            [content] => OBJECTIVE: To evaluate associations between Lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with risk of dementia and its subtypes. 
METHODS: Analysis were completed on 3320 participants of the Cardiovascular Health Study (CHS), a population-based longitudinal study of community-dwelling adults age >/=65 years followed for an average of 5.4 years. Baseline serum Lp-PLA2 mass was measured using a sandwich enzyme immunoassay and Lp-PLA2 activity utilized a tritiated-platelet activating factor activity assay. Cox proportional hazards regression assessed the relative risk of incident dementia with higher baseline Lp-PLA2 adjusting for demographics, cardiovascular disease (CVD) and risk factors, inflammation markers and apolipoprotein E (APOE) genotype.
RESULTS: Each standard deviation higher Lp-PLA2 mass and activity were related to increased risk of dementia (fully adjusted HR: 1.11 per SD, 95% CI: 1.00-1.24 for mass; HR: 1.12 per SD, 95% CI: 1.00-1.26 for activity). Persons in the highest quartile of Lp-PLA2 mass were 50% more likely to develop dementia than those in the lowest quartile in adjusted models (HR: 1.49; 95% CI: 1.08-2.06). Among dementia subtypes, the risk of AD was increased two-fold in the highest compared to lowest quartile of Lp-PLA2 mass (adjusted HR: 1.98, 95% CI: 1.22-3.21). Results were attenuated in models of mixed dementia and VaD. Lp-PLA2 activity also doubled the risk of mixed dementia in the highest compared to lowest quartile (HR: 2.21, 95% CI: 1.12-4.373). INTERPRETATION: These data support Lp-PLA2 as a risk factor for dementia independent of CVD and its risk factors. Further study is required to clarify the role of Lp-PLA2-related mechanisms in dementia subtypes. ) )